Engimmune Therapeutics: Funding, Investors & Team (Sep 2026)
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.
Engimmune Therapeutics has raised $16.3M across 2 funding rounds on record, the most recent a Seed of $15.8M announced in May 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Engimmune Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2022.
Engimmune Therapeutics Funding Rounds
Engimmune Therapeutics raised $500k in a Pre-Seed announced in Feb 2022.
3 months later, a Seed of $15.8M was announced in May 2022.
Engimmune Therapeutics Founders and Leadership Team
Contact details for the Engimmune Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Engimmune Therapeutics Funding Compared to Other Biotechnology Startups
Engimmune Therapeutics' latest round of $15.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Engimmune Therapeutics in Biotechnology and Basel
Companies Similar to Engimmune Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Engimmune Therapeutics Funding FAQs
What does Engimmune Therapeutics do?
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.
How much funding has Engimmune Therapeutics raised?
Engimmune Therapeutics has raised $16.3M across 2 rounds on record. The most recent is a Seed of $15.8M announced in May 2022.
When did Engimmune Therapeutics last raise funding?
Engimmune Therapeutics' most recent funding round on record is a Seed of $15.8M, announced in May 2022.
Who is the CEO of Engimmune Therapeutics?
Soren Mouritsen is listed as CEO at Engimmune Therapeutics.
Where is Engimmune Therapeutics headquartered?
Engimmune Therapeutics is based in Basel, Basel-Stadt, Switzerland.
How many employees does Engimmune Therapeutics have?
Engimmune Therapeutics is in the 1-10 employee band.
How does Engimmune Therapeutics' funding compare to other Biotechnology startups?
Engimmune Therapeutics' latest round of $15.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Engimmune Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Engimmune Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.